(2S)-1-(4-{[4-[3-chloro-2-fluoroanilino]-6-(2-pyrrolidin-1-ylethoxy)quinazolin-7-yl]oxy} piperidin-1-yl)-1-oxopropan-2-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: (2S)-1-(4-{[4-[3-chloro-2-fluoroanilino]-6-(2-pyrrolidin-1-ylethoxy)quinazolin-7-yl]oxy} piperidin-1-yl)-1-oxopropan-2-ol
• 英文别名: (2S)-1-[4-[4-(3-chloro-2-fluoroanilino)-6-(2-pyrrolidin-1-ylethoxy)quinazolin-7-yl]oxypiperidin-1-yl]-2-hydroxypropan-1-one
• 化学式: C₂₈H₃₃ClFN₅O₄
• 分子量: 558.053
• InChiKey: ARJZZAVABIITOD-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  39
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  100
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  N-(3-chloro-2-fluorophenyl)-7-(piperidin-4-yloxy)-6-(2-pyrrolidin-1-ylethoxy)quinazolin-4-amine trihydrochloride 、 2-过氧乙酰丙酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以45.6%的产率得到(2S)-1-(4-{[4-[3-chloro-2-fluoroanilino]-6-(2-pyrrolidin-1-ylethoxy)quinazolin-7-yl]oxy} piperidin-1-yl)-1-oxopropan-2-ol
  参考文献：
  名称：

  [EN] QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS
  [FR] DERIVES DE QUINAZOLINE UTILISES COMME INHIBITEURS DE LA TYROSINE KINASE

  摘要：

  该发明涉及配方（I）的喹唑啉衍生物；其中R1、R2、W、X1、X2、Z、a和b在描述中有定义；它们的制备方法；含有它们的药物组合物以及它们在制造用于提供抗增殖效果的药物的用途。配方（I）的喹唑啉衍生物预计在治疗某些由erbB受体酪氨酸激酶介导的癌症等疾病中具有用处，特别是EGFR酪氨酸激酶。

  公开号：

  WO2005026150A1

文献信息

• Quinazoline derivatives as tyrosine kinase inhibitors
  申请人：Hennequin Andre Laurent Francois

  公开号：US20070043009A1

  公开（公告）日：2007-02-22

  The invention concerns quinazoline derivatives of the Formula (I); wherein each of R 1 , R 2 , W, X 1 , X 2 , Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula (I) are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.

  该发明涉及式（I）的喹唑啉衍生物；其中R1，R2，W，X1，X2，Z，a和b的定义如描述中所述；它们的制备过程；含有它们的药物组合物及其用于制造提供抗增殖效应的药物的用途。预计式（I）的喹唑啉衍生物可用于治疗由erbB受体酪氨酸激酶介导的某些癌症等疾病，特别是EGFR酪氨酸激酶。
• QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS
  申请人：HENNEQUIN Laurent Francois Andre

  公开号：US20090312343A1

  公开（公告）日：2009-12-17

  The invention concerns quinazoline derivatives of the Formula I: wherein each of R 1 , R 2 , W, X 1 , X 2 , Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula I are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.

  本发明涉及式I的喹唑啉衍生物：其中R1、R2、W、X1、X2、Z、a和b如描述中所定义;它们的制备方法; 包含它们的制药组合物，以及它们在制造提供抗增殖效应的药物方面的用途。式I的喹唑啉衍生物预计可用于治疗某些由erbB受体酪氨酸激酶介导的癌症，特别是EGFR酪氨酸激酶。
• US7569577B2
  申请人：——

  公开号：US7569577B2

  公开（公告）日：2009-08-04
• [EN] QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS<br/>[FR] DERIVES DE QUINAZOLINE UTILISES COMME INHIBITEURS DE LA TYROSINE KINASE
  申请人：ASTRAZENECA AB

  公开号：WO2005026150A1

  公开（公告）日：2005-03-24

  The invention concerns quinazoline derivatives of the Formula (I); wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula (I) are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.

  该发明涉及配方（I）的喹唑啉衍生物；其中R1、R2、W、X1、X2、Z、a和b在描述中有定义；它们的制备方法；含有它们的药物组合物以及它们在制造用于提供抗增殖效果的药物的用途。配方（I）的喹唑啉衍生物预计在治疗某些由erbB受体酪氨酸激酶介导的癌症等疾病中具有用处，特别是EGFR酪氨酸激酶。